Gastrointestinal Cancer

Findings from a real-world, head-to-head comparison show greater colorectal cancer risk reduction and safety with the use of a GLP-1RA vs aspirin.

Median PFS over 1 year and median OS over 2 years have been observed for the first time in a phase 3 trial for gastroesophageal adenocarcinoma.

ECOG performance status of 1 was linked with worse patient-reported outcomes in patients with gastric or gastroesophageal junction adenocarcinoma.

Zolbetuximab plus mFOLFOX6 and nivolumab led to meaningful gains in patients with unresectable gastric/gastroesophageal junction adenocarcinoma.

As CAR T-cell therapy expands to solid tumors, oncology nurses play a key role in monitoring, educating, and supporting patients.

What should nurses know about treating patients with KRAS G12C-mutated metastatic colorectal cancer using adagrasib and cetuximab?

Catch up on recent regulatory decisions by the FDA in oncology, including actions in lung, hematologic, genitourinary, and gastrointestinal cancers.

The FDA has approved durvalumab plus FLOT for the treatment of patients with resectable gastric or gastroesophageal junction adenocarcinoma.

Durvalumab plus FLOT chemotherapy improved overall survival in resectable gastric or gastroesophageal junction cancer, per phase 3 MATTERHORN data.

Frontline lenvatinib, pembrolizumab, and chemotherapy did not lead to increased overall survival vs chemoimmunotherapy in patients with advanced ESCC.

Adding zabilugene almadenorepvec to SOC chemotherapy and nab-paclitaxel was safe and effective in patients with metastatic pancreatic ductal adenocarcinoma.

Ponsegromab increased body weight in patients with cancer-associated cachexia, yielding greater improvement in those who received ponsegromab previously.

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median injection time of 2 minutes.

In a phase 1 study, ELI-002 2P improved relapse-free survival in pancreatic and colorectal cancer, with stronger benefit in patients with T-cell responses.

A care model led by advanced practice nurses was feasible in providing supportive care and linking providers through post-trial care transitions.

The addition of retifanlimab to chemotherapy increased progression-free survival in patients with advanced squamous cell carcinoma of the anal canal.

Oncology nurses can assess patients’ risk factors and advocate for preventive strategies that protect kidney function during cisplatin therapy.

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

The novel MEK inhibitor atebimetinib plus chemotherapy showed early signs of survival benefit in first-line treatment of patients with pancreatic cancer.

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

Adding panitumumab to neoadjuvant FOLFOX cut recurrence risk and improved survival in locally advanced, RAS/BRAF wild-type colon cancer.

Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.

Assessing the signs and symptoms of chemotherapy-induced diarrhea and providing accurate and timely patient education may reduce complications and optimize survival outcomes.

The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.